TATUM bioscience is a synthetic biology company developing a new class of biologics called synthetic advanced biologics. The company was founded on the premise that more than 50 percent of cancer patients do not respond to checkpoint inhibitor treatments and are left with no therapeutic solutions. Combination therapies are currently put forward to address this issue, however this approach ends up multiplying treatments, side effects, and costs. TATUM bioscience is building a first-in-class proprietary immuno-oncology platform articulated around synthetic advanced biologics (synABs) capable of multi-tasking therapeutic activities. SynABs pack all the advantages of combination therapy into a single biologic, providing safer and more efficient cancer treatments.